Tenax Therapeutics, Inc. (TENX)
NASDAQ
Healthcare
Biotechnology
$14.79
▼ -5.92%
Market Cap
$254.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.91
52-Wk Range
5.78-19.4
CEO
Christopher T. Giordano
Country
US
Currency
USD
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is…
Open full interactive analysis & DCF →